Inclusion Criteria:

          1. 18 years or over.

          2. Written (signed and dated) informed consent and willing and capable of co-operating
             with study procedures, treatment and follow-up.

          3. Histologically proven advanced or metastatic solid tumours.

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          5. Life expectancy of at least 12 weeks.

          6. Haematological and biochemical indices (within 7 days before the first dose of
             CCT3833) within the ranges shown below:

               1. Haemoglobin (Hb) ≥ 9.0 g/dL.

               2. Absolute neutrophil count ≥ 1.5 x 109/L.

               3. Platelet count ≥ 100 x 109/L.

               4. Total bilirubin ≤ 1.5 x upper limit of normal (ULN), and Alanine aminotransferase
                  (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x (ULN) (or ≤ 5 x ULN if
                  elevated due to tumour).

               5. Calculated creatinine clearance > 50 mL/min (based on Cockcroft-Gault
                  calculation).

          7. Negative pregnancy test for females of child-bearing age.

        Inclusion criteria: dose expansion cohort

        Patients must meet ALL of the above criteria and additionally meet the following criteria:

          1. Histologically proven locally advanced (unresectable) or metastatic melanoma.

          2. Documented presence of either BRAF or RAS mutations, as established by validated
             mutation testing from tumour biopsy.

          3. Evidence of measurable disease (according to RECIST v1.1)

        Exclusion Criteria:

        Patients who meet ANY of the following criteria will not be eligible to participate.

        Patients who have had any of the following within the last 4 weeks:

          1. Radiotherapy (except for palliative reasons), endocrine therapy (except luteinizing
             hormone releasing hormone (LHRH) agonists for prostate cancer), immunotherapy or
             chemotherapy (6 weeks for nitrosoureas, Mitomycin-C and 4 weeks for other
             investigational medicinal products (IMP)) before treatment. (For patients recruited to
             Part B (dose expansion) from Part A (dose escalation), prior treatment with CCT3833
             during Part A (dose escalation) is permissible.)

          2. Major surgery within the last four weeks.

          3. Has been a participant in another interventional research study (involving an IMP)
             within the last 4 weeks, or plans to participate in one whilst taking part in this
             study. Participation in an observational study would be acceptable.

             Patients who have any of the following:

          4. High medical risk because of non-malignant systemic disease including active,
             uncontrolled infection.

          5. Known allergy to any pharmaceutical excipients.

          6. Known to be serologically positive for Hepatitis B, Hepatitis C or Human
             Immunodeficiency Virus (HIV). Testing for these viruses is not mandatory.

          7. Impaired cardiac function or clinically significant cardiac diseases, including any of
             the following:

               1. History or presence of ventricular tachyarrhythmia.

               2. Presence of unstable atrial fibrillation (ventricular response > 100 bpm);
                  patients with stable atrial fibrillation are eligible, provided they do not meet
                  any of the other cardiac exclusion criteria.

               3. Repeated presence of a prolonged QTc interval > 450 ms at baseline (as calculated
                  by Fridericia method).

               4. Unstable angina pectoris or acute myocardial infarction in the last 12 months
                  prior to starting study drug.

               5. Other clinically significant heart disease (e.g., symptomatic congestive heart
                  failure (LVEF < 50%); uncontrolled arrhythmia; history of labile hypertension or
                  poor compliance with an antihypertensive regimen).

          8. Uncontrolled hypertension that remains uncontrolled on > 1 antihypertensive agent.

          9. Symptomatic brain metastases (if present they must have been stable for > 3 months).
             Such patients must not be requiring systemic corticosteroid or enzyme-inducing
             anticonvulsant therapy.

         10. Inability to take oral medication; impairment of GI function or GI disease that could
             interfere with drug absorption.

         11. Have taken potent inducers/inhibitors of CYP3A4 and CYP2C8 liver enzymes within 2
             weeks of the first administration of study drug, or have conditions that require the
             concomitant usage of such drugs during the course of the study.

         12. Are taking warfarin as an oral anticoagulant; patients anticoagulated with low
             molecular weight heparin are not excluded from the trial.

         13. Female patients who are pregnant or lactating, or have the ability to become pregnant.
             However, those female patients who have a negative serum or urine pregnancy test
             before enrolment and are using highly-effective contraception during the study and for
             6 months afterwards, are considered eligible. Highly-effective contraception methods
             include:

               1. Total abstinence.

               2. Male or female sterilization.

               3. A combination of any two of the following:

             i. Oral, injected or implanted hormonal contraception. ii. Placement of an
             intrauterine device (IUD) or intrauterine system (IUS). iii. Barrier methods of
             contraception: condom or diaphragm with spermicidal foam/gel/film/cream/vaginal
             suppository.

         14. Male patients with partners of child-bearing potential, unless they agree to take
             measures not to father children by using one form of highly effective contraception as
             defined above, during the study and for 6 months afterwards. Men with pregnant or
             lactating partners should be advised to use barrier method contraception to prevent
             exposure to the foetus or neonate.

         15. Any other condition which in the Investigator's opinion would not make the patient a
             good candidate for the clinical study.